PFS was defined as the time from randomization to the first observation of disease progression (as classified by modified RECIST), symptomatic deterioration or death due to any cause, whichever occurs first. Disease progression per RECIST is defined as at least a 20% increase in the sum of diameters of target lesions in reference to the smallest sum on study and an absolute increase of at least 5 mm; the appearance of any new lesions is also considered progression.

Graded Using the National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE) Version 3.0

Serum AMG 479 Concentrations After IV Administration of 12 mg/kg AMG 479 in combination with Exemestane, and in combination with Fulvestrant (Cmax).

PK population, included only subjects who received the specified combination.

Clinical benefit was defined as complete/partial response, or stable disease≥24 weeks per modified RECIST/local review.

Objective response rate was defined as complete/partial response per modified RECIST/local review.

Per Response Evaluation Criteria in Solid Tumors [RECIST]: a complete response is the disappearance of all target lesions; a partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable disease is disease that is not complete, partial or progressive (PD = at least a 20% increase in the sum of diameters of target lesions in reference to the smallest sum on study)

All Randomized Subjects with Baseline Tumor Assessment

Duration of response was defined as time from the date of first confirmed response to the date of first disease progression or death due to any cause in a subset of subjects with confirmed response.

Time to response was defined as the interval in days from randomization to the first assessment of objective response (CR or PR).

A complete response is the disappearance of all target lesions; a partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease is at least a 20% increase in the sum of diameters of target lesions in reference to the smallest sum on study.

Subjects with Baseline Measureable Disease and Confirmed Response

Time to progression was defined as the time from date of randomization to the date of first occurrence of disease progression or death due to disease progression

Time to treatment failure was defined as the time from date of randomization to the earliest date of disease progression, death, or end of cycle [last dose date + 1 cycle time: 14 days] for the last dose of ganitumab or placebo regardless of the reason of discontinuation

Overall survival was defined as the time from randomization to death.

Progressive disease is at least a 20% increase in the sum of diameters of target lesions in reference to the smallest sum on study.

Based on the European Organization Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C-30) v3, a 30-item questionnaire comprised of 5 functional scales, 3 symptom scales, and 6 single item scales, all with scores ranging from 1=not at all to 4=very much, along with the Health-Related Quality of Life scale with scores ranging from 1=very poor to 7=excellent; and 2 questions from the Dermatology Life Quality Index (DLQI; scores ranged from 1=not at all to 4=very much). Summing of all these questions and standardizing yielded a total score ranging from 0-100; higher total scores = better quality of life.

AUC of the change from baseline of the mean total score over time were calculated using the linear trapezoidal rule. The time-adjusted AUC was calculated by dividing the AUC by the time interval between baseline and the last scheduled assessment, the difference was analyzed using analysis of covariance with baseline score and stratification factors as covariates.

The European Organization for Research and Treatment of Cancer (EORTC) analysis set consisted of all subjects in the full analysis set who had a baseline and at least

1 postbaseline non-missing measurable score of the EORTC QLQ-C30 questionnaire for descriptive comparisons between treatment groups.